Come up with a name for your new list and we'll add to it:
Intellikine raised a round of funding on March 05, 2010. Investors include
Multiple Myeloma Research Foundation.
Intellikine is developing small molecule therapies targeting the PI3K/mTOR pathway for treatment of cancer, inflammation and autoimmune diseases. In December 2011, Intellikine was acquired by Taked…